LY9 and Miyoshi myopathy: Co-IP experiments verified that phosphorylation of CD229 and expression of RASAL3 were blunted after Dasatinib treatment in CD229-OE MM cells, indicating the impaired interaction between CD229 and RASAL3 (Figure 6A).